Exact Sciences Dirección
Dirección controles de criterios 2/4
El CEO de Exact Sciences es Kevin Conroy , nombrado en Apr 2009, tiene una permanencia de 15.58 años. compensación anual total es $16.12M, compuesta por 6.5% salario y 93.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.38% de las acciones de la empresa, por valor de $36.25M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 5.7 años, respectivamente.
Información clave
Kevin Conroy
Chief Executive Officer (CEO)
US$16.1m
Compensación total
| Porcentaje del salario del CEO | 6.5% |
| Permanencia del CEO | 15.6yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 3.8yrs |
| Promedio de permanencia en la Junta Directiva | 5.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge
Nov 10
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Sep 25Exact Sciences: Cost Optimization And Product Strength
Aug 18Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Aug 14Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$214m |
| Jun 30 2024 | n/a | n/a | -US$175m |
| Mar 31 2024 | n/a | n/a | -US$240m |
| Dec 31 2023 | US$16m | US$1m | -US$204m |
| Sep 30 2023 | n/a | n/a | -US$282m |
| Jun 30 2023 | n/a | n/a | -US$432m |
| Mar 31 2023 | n/a | n/a | -US$517m |
| Dec 31 2022 | US$14m | US$510k | -US$624m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$735m |
| Mar 31 2022 | n/a | n/a | -US$745m |
| Dec 31 2021 | US$15m | US$963k | -US$596m |
| Sep 30 2021 | n/a | n/a | -US$793m |
| Jun 30 2021 | n/a | n/a | -US$829m |
| Mar 31 2021 | n/a | n/a | -US$720m |
| Dec 31 2020 | US$20m | US$499k | -US$824m |
| Sep 30 2020 | n/a | n/a | -US$327m |
| Jun 30 2020 | n/a | n/a | -US$165m |
| Mar 31 2020 | n/a | n/a | -US$136m |
| Dec 31 2019 | US$19m | US$792k | -US$213m |
| Sep 30 2019 | n/a | n/a | -US$216m |
| Jun 30 2019 | n/a | n/a | -US$221m |
| Mar 31 2019 | n/a | n/a | -US$219m |
| Dec 31 2018 | US$7m | US$696k | -US$175m |
| Sep 30 2018 | n/a | n/a | -US$143m |
| Jun 30 2018 | n/a | n/a | -US$124m |
| Mar 31 2018 | n/a | n/a | -US$119m |
| Dec 31 2017 | US$13m | US$633k | -US$114m |
Compensación vs. Mercado: La compensación total de Kevin($USD16.12M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD7.84M).
Compensación vs. Ingresos: La compensación de Kevin ha aumentado mientras la empresa no es rentable.
CEO
Kevin Conroy (58 yo)
15.6yrs
Permanencia
US$16,119,899
Compensación
Mr. Kevin T. Conroy served as Independent Director of SomaLogic, Inc. since September 1, 2021, until January 2022. Mr. Conroy had served as an Independent Director of Adaptive Biotechnologies Corporation s...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of The Board & CEO | 15.6yrs | US$16.12m | 0.38% $ 36.2m | |
| Executive VP & GM of Screening | no data | US$3.67m | 0.0084% $ 792.7k | |
| Executive VP & General Manager of Precision Oncology | no data | US$3.57m | 0.0071% $ 673.0k | |
| Executive Vice President of Finance | less than a year | sin datos | sin datos | |
| Chief Science Officer | 3.6yrs | sin datos | sin datos | |
| Chief Information Officer | 1.8yrs | sin datos | sin datos | |
| Associate Manager of Investor Relations | no data | sin datos | sin datos | |
| Chief Compliance Counsel & VP | 9.8yrs | sin datos | sin datos | |
| Senior VP | 2.8yrs | sin datos | 0.0060% $ 562.7k | |
| Executive Vice President of Human Resources | 7.5yrs | US$2.71m | 0.042% $ 4.0m | |
| Emeritus Chief Science Officer | 3.8yrs | US$4.21m | sin datos | |
| Chief Laboratory Officer | 9.3yrs | US$3.95m | sin datos |
3.8yrs
Permanencia media
50yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de EXAS se considera experimentado (3.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of The Board & CEO | 15.7yrs | US$16.12m | 0.38% $ 36.2m | |
| Independent Director | 14.3yrs | US$408.75k | 0.015% $ 1.4m | |
| Director | 1.9yrs | US$1.47m | 0.030% $ 2.8m | |
| Independent Director | 15.6yrs | US$406.25k | 0.038% $ 3.6m | |
| Independent Director | less than a year | sin datos | 0.0029% $ 277.1k | |
| Independent Director | 3.7yrs | US$417.75k | 0.011% $ 1.0m | |
| Independent Director | 5.7yrs | US$411.75k | 0.017% $ 1.6m | |
| Independent Director | 4.3yrs | US$401.25k | 0.012% $ 1.2m | |
| Lead Independent Director | 10.3yrs | US$442.75k | 0.030% $ 2.8m |
5.7yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de EXAS se considera experimentada (5.7 años de antigüedad promedio).